Zacks Research Has Negative Outlook of BIO FY2025 Earnings

Bio-Rad Laboratories, Inc. (NYSE:BIO) – Stock analysts at Zacks Research lowered their FY2025 earnings per share (EPS) estimates for shares of Bio-Rad Laboratories in a research note issued to investors on Wednesday, November 19th. Zacks Research analyst Team now expects that the medical research company will post earnings per share of $9.98 for the year, down from their prior estimate of $10.02. Zacks Research has a “Hold” rating on the stock. The consensus estimate for Bio-Rad Laboratories’ current full-year earnings is $10.81 per share. Zacks Research also issued estimates for Bio-Rad Laboratories’ Q4 2026 earnings at $2.60 EPS, Q1 2027 earnings at $2.12 EPS and Q2 2027 earnings at $2.44 EPS.

Bio-Rad Laboratories (NYSE:BIO) last released its earnings results on Wednesday, October 29th. The medical research company reported $2.26 earnings per share for the quarter, missing analysts’ consensus estimates of $2.30 by ($0.04). Bio-Rad Laboratories had a positive return on equity of 4.18% and a negative net margin of 26.43%.The firm had revenue of $653.00 million for the quarter, compared to the consensus estimate of $651.30 million. During the same quarter in the previous year, the firm earned $2.01 EPS. The company’s revenue was up .5% compared to the same quarter last year. Bio-Rad Laboratories has set its FY 2025 guidance at EPS.

Other equities research analysts have also recently issued research reports about the stock. Royal Bank Of Canada lifted their price target on shares of Bio-Rad Laboratories from $387.00 to $409.00 and gave the stock an “outperform” rating in a research report on Friday, August 1st. Wells Fargo & Company lifted their target price on shares of Bio-Rad Laboratories from $265.00 to $340.00 and gave the stock an “equal weight” rating in a report on Thursday, October 30th. Weiss Ratings lowered Bio-Rad Laboratories from a “hold (c-)” rating to a “sell (d-)” rating in a research report on Thursday, November 13th. Citigroup lifted their price objective on Bio-Rad Laboratories from $350.00 to $375.00 and gave the stock a “buy” rating in a research note on Thursday, October 30th. Finally, Wall Street Zen upgraded Bio-Rad Laboratories from a “hold” rating to a “buy” rating in a report on Saturday, November 1st. Three analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $358.50.

Bio-Rad Laboratories Stock Performance

Shares of NYSE:BIO opened at $304.85 on Thursday. The company has a current ratio of 5.12, a quick ratio of 3.67 and a debt-to-equity ratio of 0.17. Bio-Rad Laboratories has a 1-year low of $211.43 and a 1-year high of $373.69. The stock has a market capitalization of $8.22 billion, a P/E ratio of -12.54 and a beta of 1.04. The business has a 50-day moving average price of $303.62 and a two-hundred day moving average price of $271.46.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of BIO. First Eagle Investment Management LLC increased its position in shares of Bio-Rad Laboratories by 60.7% during the second quarter. First Eagle Investment Management LLC now owns 2,517,313 shares of the medical research company’s stock worth $607,478,000 after acquiring an additional 951,123 shares in the last quarter. Dimensional Fund Advisors LP boosted its stake in Bio-Rad Laboratories by 6.3% in the 3rd quarter. Dimensional Fund Advisors LP now owns 1,062,938 shares of the medical research company’s stock worth $298,019,000 after purchasing an additional 63,370 shares during the period. Ariel Investments LLC boosted its stake in Bio-Rad Laboratories by 13.0% in the 2nd quarter. Ariel Investments LLC now owns 818,624 shares of the medical research company’s stock worth $197,550,000 after purchasing an additional 93,964 shares during the period. Earnest Partners LLC boosted its stake in Bio-Rad Laboratories by 0.6% in the 3rd quarter. Earnest Partners LLC now owns 609,284 shares of the medical research company’s stock worth $170,837,000 after purchasing an additional 3,398 shares during the period. Finally, Bank of America Corp DE raised its stake in shares of Bio-Rad Laboratories by 1.7% in the 3rd quarter. Bank of America Corp DE now owns 459,887 shares of the medical research company’s stock valued at $128,948,000 after purchasing an additional 7,754 shares during the period. Institutional investors own 65.24% of the company’s stock.

Insider Buying and Selling at Bio-Rad Laboratories

In related news, EVP James Barry sold 700 shares of the business’s stock in a transaction that occurred on Thursday, November 6th. The stock was sold at an average price of $306.18, for a total value of $214,326.00. Following the completion of the transaction, the executive vice president directly owned 510 shares in the company, valued at approximately $156,151.80. The trade was a 57.85% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. 17.06% of the stock is owned by company insiders.

About Bio-Rad Laboratories

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.